Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Fluvoxamine interaction with warfarin.

Limke KK, Shelton AR, Elliott ES.

Ann Pharmacother. 2002 Dec;36(12):1890-2.

PMID:
12452751
2.

Interaction of fluvoxamine with warfarin in an elderly woman.

Yap KB, Low ST.

Singapore Med J. 1999 Jul;40(7):480-2.

PMID:
10560276
3.

[A Case with the Increased PT-INR after the Addition of Mirtazapine to Warfarin Therapy].

Nishimura H, Kawakami M.

Seishin Shinkeigaku Zasshi. 2015;117(10):820-5. Japanese.

PMID:
26827407
4.

Elevated international normalized ratio associated with use of dronedarone and warfarin.

Pogge EK, Haber SL.

Ann Pharmacother. 2011 Sep;45(9):e46. doi: 10.1345/aph.1Q217. Epub 2011 Aug 2.

PMID:
21811004
5.

Role of desethylamiodarone in the anticoagulant effect of concurrent amiodarone and warfarin therapy.

Naganuma M, Shiga T, Nishikata K, Tsuchiya T, Kasanuki H, Fujii E.

J Cardiovasc Pharmacol Ther. 2001 Oct;6(4):363-7.

PMID:
11907638
6.

Warfarin-cranberry juice interaction.

Hamann GL, Campbell JD, George CM.

Ann Pharmacother. 2011 Mar;45(3):e17. doi: 10.1345/aph.1P451. Epub 2011 Mar 1.

PMID:
21364039
7.

Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19).

Christensen M, Tybring G, Mihara K, Yasui-Furokori N, Carrillo JA, Ramos SI, Andersson K, Dahl ML, Bertilsson L.

Clin Pharmacol Ther. 2002 Mar;71(3):141-52.

PMID:
11907488
8.

Warfarin and bosentan interaction in a patient with pulmonary hypertension secondary to bilateral pulmonary emboli.

Spangler ML, Saxena S.

Clin Ther. 2010 Jan;32(1):53-6. doi: 10.1016/j.clinthera.2010.01.004.

PMID:
20171411
9.

Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.

Vaz-da-Silva M, Almeida L, Falcão A, Soares E, Maia J, Nunes T, Soares-da-Silva P.

Clin Ther. 2010 Jan;32(1):179-92. doi: 10.1016/j.clinthera.2010.01.014.

PMID:
20171423
10.

Enhanced anticoagulant effect of warfarin in a patient treated with cloxacillin.

Marusic S, Gojo-Tomic N, Bacic-Vrca V, Franic M.

Int J Clin Pharmacol Ther. 2012 Jun;50(6):431-3.

PMID:
22677303
11.

Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.

Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brøsen K.

Eur J Clin Pharmacol. 1996;51(1):73-8.

PMID:
8880055
12.

Probable warfarin and dapsone interaction.

Truong T, Haley J.

Clin Appl Thromb Hemost. 2012 Jan-Feb;18(1):107-9. doi: 10.1177/1076029611418963. Epub 2011 Sep 2.

PMID:
21890570
13.

The effect of erythromycin, fluvoxamine, and their combination on the pharmacokinetics of ropivacaine.

Jokinen MJ, Ahonen J, Neuvonen PJ, Olkkola KT.

Anesth Analg. 2000 Nov;91(5):1207-12.

PMID:
11049910
14.

Fluvoxamine but not citalopram increases serum melatonin in healthy subjects-- an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin.

von Bahr C, Ursing C, Yasui N, Tybring G, Bertilsson L, Röjdmark S.

Eur J Clin Pharmacol. 2000 May;56(2):123-7.

PMID:
10877005
15.

Orlistat enhances warfarin effect.

MacWalter RS, Fraser HW, Armstrong KM.

Ann Pharmacother. 2003 Apr;37(4):510-2.

PMID:
12659605
16.

Ifosfamide and etoposide chemotherapy may interact with warfarin, enhancing the warfarin induced anticoagulant response.

Okada N, Watanabe H, Kagami S, Ishizawa K.

Int J Clin Pharmacol Ther. 2016 Jan;54(1):58-61. doi: 10.5414/CP202426.

PMID:
26587904
17.

Possible interaction between warfarin and Lycium barbarum L.

Lam AY, Elmer GW, Mohutsky MA.

Ann Pharmacother. 2001 Oct;35(10):1199-201.

PMID:
11675844
18.

Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo.

Ozdemir V, Naranjo CA, Shulman RW, Herrmann N, Sellers EM, Reed K, Kalow W.

J Clin Psychopharmacol. 1998 Jun;18(3):198-207.

PMID:
9617978
19.

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.

Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padrini R.

Clin Pharmacol Ther. 2002 Dec;72(6):702-10.

PMID:
12496751
20.

Supplemental Content

Support Center